Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis

Clinical Drug Investigation

Volumn 24, Issue 11, 2004, Pages 633-639

  Davis, George A ^a   Rudy, Anita C ^b   Archer, Sanford M ^c   Wermeling, Daniel P ^a   McNamara, Patrick J ^a  

^a University of Kentucky   (United States)

^b Intranasal Technology Incorporated   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROMORPHONE; OXYMETAZOLINE; PSEUDOEPHEDRINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; FIRST PASS EFFECT; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SOMNOLENCE; STEADY STATE; TASTE DISORDER; VASOMOTOR RHINITIS;

EID: 9644281425     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424110-00002     Document Type: Article

References (21)

1. Mahler DL, Forrest Jr WH. Relative analgesic potencies of morphine and hydromorphone in postoperative pain. Anesthesiology 1975; 42: 602-7
2. Dilaudid® (hydromorphone hydrochloride) product information. Whippany (NJ): Knoll Pharmaceutical, 1996
3. McEvoy GK, Litvak K, Welsh OH, et al., editors. American hospital formulary service drug information. Bethesda (MD): American Society of Health-System Pharmacists, 2001
4. Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001; 9: 84-96
5. Vallner JJ, Stewart JT, Kotzan JA, et al. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol 1981; 21: 152-6
6. Ritschel WA, Parab PV, Denson DD, et al. Absolute bioavailability of hydromorphone after peroral and rectal administration in humans: saliva/plasma ratio and clinical effects. J Clin Pharmacol 1987; 27: 647-53
7. Parab PV, Ritschel WA, Coyle DE, et al. Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. Biopharm Drug Dispos 1988; 9: 187-99
8. Drover DR, Angst MS, Valle M, et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 2002; 97: 827-36
9. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002; 46: 759-70
10. Dykewicz MS. 7. Rhinitis and sinusitis. J Allergy Clin Immunol 2003; 111 Suppl. 2: 520-9
11. Settipane RA, Lieberman P. Update on nonallergic rhinitis. Ann Allergy Asthma Immunol 2001; 86: 494-507
12. Proost JH. Wagner's exact Loo-Riegelman equation: the need for a criterion to choose between the linear and logarithmic trapezoidal rule. J Pharm Sci 1985 Jul; 74: 793-4
13. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1982
14. Coda BA, Rudy AC, Archer SM, et al. Pharmacokinetics and bioavailability of single dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg 2003; 97: 117-23
15. Reidenberg MM, Goodman H, Erie H, et al. Hydromorphone levels and pain control in patients with severe chronic pain. Clin Pharmacol Ther 1988; 44: 376-82
16. Inturrisi CE, Portenoy RK, Stillman M, et al. Pharmacokinetic- pharmacodynamic relationships of methadone infusions in patients with cancer pain. Clin Pharmacol Ther 1990; 47: 565-77
17. Shyu WC, Pittman KA, Robinson DS, et al. The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. Eur J Clin Pharmacol 1993; 45: 559-62
18. Larsen C, Niebuhr Jorgensen M, Tommerup B, et al. Influence of experimental rhinitis on the gonadotropin response to intranasal administration of buserelin. Eur J Clin Pharmacol. 1987; 33 (2): 155-9
19. Argenti D, Colligon I, Heald D, et al. Nasal mucosal inflammation has no effect on the absorption of intranasal triamcinolone acetonide. J Clin Pharmacol 1994; 34: 854-8
20. Olanoff LS, Titus CR, Shea MS, et al. Effect of intranasal histamine on nasal mucosal blood flow and the antidiuretic activity of desmopressin. J Clin Invest 1987; 80: 890-5
21. Chang SF, Moore L, Chien YW. Pharmacokinetics and bioavailability of hydromorphone: effect of various routes of administration. Pharm Res 1988; 5: 718-21